A trial fibrillation (AF) promotes its own maintenance by causing tachycardia-induced electrophysiological and structural remodeling of the atrial myocardium. 1, 2 One potential link between AF, tachycardia, and atrial remodeling is oxidative stress. Consistent with this hypothesis, rapid atrial pacing has been shown to increase myocardial peroxynitrite formation and lead to a shortening of the atrial effective refractory period (ERP), both of which are reversed by treatment with the antioxidant and peroxynitrite decomposition catalyst ascorbate. 3 More recently, administration of other agents with antioxidant and anti-inflammatory properties such as statins has proved similarly effective in preventing ERP shortening and the vulnerability to AF in a dog model of rapid atrial pacing. 4 The mechanisms underlying oxidative injury in the fibrillating atrial myocardium remain to be elucidated; however, an increasing body of evidence indicates that formation of the oxygen-derived free radical superoxide by NAD(P)H oxidases plays a critical role in the development of a wide range of cardiovascular diseases, [5] [6] [7] suggesting that this oxidase system may be an important source of oxidative injury in the fibrillating human atrial myocardium.
In neutrophils, NAD(P)H oxidase consists of a core heterodimer comprising the electron transferring plasma membrane subunits p22 phox and gp91 phox (or nox2) and 4 cytosolic subunits (p40 phox , p47 phox , p67 phox , and the small G-protein rac1/2), which provide regulatory function. 5 In vascular smooth muscle and endothelial cells, gp91 phox coexists with other homologues termed nox1 and nox4, 8 -10 whereas a gp91 phox containing NAD(P)H oxidase is the most common isoform in the human ventricular myocardium. 7, 11 Here, we investigated the source of atrial superoxide production in right atrial appendage (RAA) homogenates and in isolated atrial myocytes from patients in sinus rhythm (SR) undergoing cardiac surgery. We then examined whether the presence of AF affected the magnitude or source of superoxide production in RAA homogenates obtained from patients with permanent or paroxysmal AF. isolated intact atrial myocytes) were performed in RAAs obtained from 39 patients in SR who underwent first-time coronary artery bypass surgery with or without mitral/aortic valve replacement.
In addition, we evaluated superoxide production and its sources and the expression of NAD(P)H oxidase subunits in RAA homogenates obtained from 15 patients with a history of AF and 15 patients in SR with no previous history of arrhythmias who were matched for treatment, age, and other known risk factors for cardiovascular disease. The AF group included 6 patients who had permanent AF and 9 who had a history of symptomatic paroxysmal AF or persistent AF 12 for which they had previous cardioversion. Of these 9 patients, 4 were in AF at the time of admission. We grouped these patients together because of evidence indicating that paroxysmal AF in humans is associated with electrophysiological and structural changes of the atrial myocardium that are similar to those observed in patients with permanent AF, [13] [14] [15] suggesting that intermittent bursts of AF, particularly if frequent, are sufficient to instigate atrial remodeling in humans.
A preoperative left ventricular ejection fraction (LVEF; %) was obtained in all patients, whereas left atrial size (by transthoracic echocardiography) was obtained in 24 (14 in AF and 10 in SR) of the 30 patients included in the matched cohort. Demographic and clinical characteristics of the three groups are shown in Table 1 . The study was approved by the local research ethics committee, and all patients gave written informed consent.
Atrial Myocyte Isolation Protocol
Samples of RAA were digested (40 minutes) in isolation buffer supplemented with type I collagenase (2 mg/mL; Worthington) and protease (0.2 mg/mL; Sigma), 1% BSA, and 50 mol/L Ca 2ϩ , and then transferred into fresh collagenase solution without protease. After isolation, rod-shaped atrial myocytes were enriched (to Ϸ90%) by a two-step centrifugation (3 minutes at 600 rpm) in Kraft-Bruhe medium supplemented with L-glutamate, sodium pyruvate, taurine, creatine, succinic acid, Na 2 ATP, and ␤-OH butyrate and used within 3 hours for superoxide measurements.
Atrial Superoxide Production
Superoxide production in homogenized RAAs or isolated atrial myocytes was measured by lucigenin-enhanced chemiluminescence using a single-tube luminometer (Berthold FB12) modified to maintain the sample temperature at 37°C. 16 Briefly, basal chemiluminescence from RAA homogenate or isolated right atrial myocytes was measured in buffer (2 mL) containing lucigenin (5 mol/L) after reaching equilibrium (Ϸ7 minutes). Further measurements were taken after the addition of inhibitors or substrates of specific oxidase systems 16 (Table 2; nϭ9 to 14 for each comparison) . Superoxide scavengers such as polyethylene glycol-superoxide dismutase (PEG-SOD; 650 U/mL) and tiron (10 mmol/L) were also used.
After application of NADPH (100 mol/L), the chemiluminescence signal in RAA homogenate reached a plateau within 3 minutes; however, in atrial myocytes, the signal continued to increase linearly over time. Hence, in this preparation, measurements do not reflect the maximal NADPH-stimulated superoxide production. Atrial homogenates were separated into soluble (cytosolic) and particulate (membrane-associated) fractions by ultracentrifugation, as described previously. 17 Because lucigenin (at concentration Ն20 mol/L) may be subject to redox cycling, 18 we compared basal and NADPH-stimulated superoxide measurements in RAA homogenates by 5 mol/L lucigenin with those obtained by using the luminol analogue L-012 (100 mol/L in the presence of ebselen; 50 mol/L) 19, 20 and the SOD-inhibitable ferricytochrome c reduction, 16, 21 respectively. In both cases, measurements were closely correlated with those obtained in parallel by lucigenin-enhanced chemiluminescence (basal measurements rϭ0.88, PϽ0.005, nϭ8; NADPH-stimulated rϭ0.99, PϽ0.0001, nϭ11), in agreement with previous reports indicating that 5 mol/L lucigenin is a sensitive and valid probe for assessing superoxide production. 22, 23 
Flavin-containing oxidases DPI (10 or 100 mol/L)
Oxidative Fluorescent Microtopography Using Dihydroethidium
Superoxide production in tissue sections of human RAA was detected using the fluorescent probe DHE. 24 Human RAAs were freshly harvested and frozen in OCT compound. Cryosections (30 m) were incubated in Krebs-HEPES buffer for 30 minutes at 37°C with or without PEG-SOD (1000 U/mL) and with dihydroethidium (DHE; 2 mol/L; Molecular Probes) for another 5 minutes at 37°C in darkness. Images were obtained using a laser confocal microscope (Bio-Rad; MRC 1024) at identical acquisition settings using an excitation wavelength of 488 nm. Fluorescence was detected at 585 nm.
Immunoblotting
Protein expression of subunits of NAD(P)H oxidase in RAA homogenates was investigated using rabbit polyclonal antibodies directed against cytosolic p47 phox and p67 phox subunits (07-001 and 07-002; Upstate) and a rabbit polyclonal antibody directed against the p22 phox subunit (a kind gift from Dr Frans B. Wientjes, University College London, United Kingdom) after separation in 10% SDS-PAGE gels and protein transfer to polyvinylidene difluoride membranes. After incubation in primary antibody, antibody binding was visualized using horseradish peroxidase-conjugated anti-rabbit IgG (Promega) chemiluminescence.
Immunolocalization
Freshly isolated human atrial myocytes were concentrated by centrifugation (600 rpm; 3 minutes). Myocytes were plated on laminin (60 g/mL)-coated coverslips and fixed (1.5 hours at room temperature) by applying 50 L of cooled 4% paraformaldehyde containing 0.2% Triton X-100. Coverslips were washed with PBS three times and then blocked (2 hours at room temperature) with 5% BSA. Cells were incubated with the primary antibody (1 hour at room temperature; rabbit polyclonal anti-p47 phox or anti-p67 phox Ab, 07-001 and 07-002; Upstate) diluted 1:500 in PBS containing 5% BSA, washed in PBS, then incubated (30 minutes) with 1:50 fluorescenceconjugated goat anti-rabbit IgG (Alexis). Fluorescence images were obtained with a Bio-Rad MRC 1024 scanning confocal microscope.
Conventional and Quantitative Real-Time RT-PCR
Conventional RT-PCR was initially used to evaluate the presence of gp91 phox /nox2, its homologues nox1 and nox4, and p22 phox in RAA homogenates of patients in SR. Optimal PCR conditions were 100 nmol/L primers for p22 phox , gp91 phox , nox1, and nox4 (Table 3) phox , nox1, and nox4 cDNA generated 341-, 225-, 377-, and 516-bp fragments, respectively, and were resolved on 2% agarose gel.
Quantitative real time RT-PCR (Rotor-Gene 3000; Corbett Research) was used to compare the expression level of the primary transcripts for p22 phox and gp91 phox /nox2 subunits of NAD(P)H oxidase in patients with AF and their matched controls in SR. Total RNA was extracted from RAA using a double Trizol extraction procedure, with the resulting RNA pellet treated with amplification grade DNase (Invitrogen). Total RNA was then quantified using RiboGreen, adjusted to 25 ng/uL, and then subjected to one-step reverse transcription and PCR amplification ( Table 2) using QuantiTect SYBR Green (Qiagen) in the following conditions: 2.5-pmol/L primers for gp91 phox and p22 phox , 2.5 mmol/L MgCl 2 , annealing at 60°C, extension at 72°C. Arbitrary copy numbers were analyzed using Rotor-Gene v.5 software (Corbett Research) from standard curves generated from serial dilutions of total RNA extracted from RAAs for human p22 phox and gp91 phox templates.
Statistical Analysis
Data are expressed as meanϮSEM unless specified otherwise. In all cases, n refers to numbers of patients. Nonparametric statistics was used to evaluate some of the responses to inhibitors or substrates of oxidases and the differences in mRNA expression between AF and SR patients. Other comparisons were made by using ANOVA and Fisher's protected least significant difference post hoc test. A value of PϽ0.05 was considered statistically significant.
Results

Sources of Superoxide Production in RAA Homogenates and Isolated Myocytes From Patients in SR
Basal superoxide production was determined by lucigenin (5 mol/L)-enhanced chemiluminescence in homogenized RAAs and in intact right atrial myocytes (average 80Ϯ8 relative light units [RLU]/mg protein; nϭ39 patients; and 0.031Ϯ0.006 RLU/myocyte; nϭ16 patients, respectively). Specificity for superoxide was demonstrated by nearabolition of chemiluminescence after coincubation with either PEG-SOD (650 U/mL) or tiron (10 mmol/L; Figure 1A ). In addition, basal superoxide production was greatly reduced by the inhibitor of flavin-containing oxidases, diphenyleneiodonium (DPI; 100 mol/L in RAA and 10 mol/L in atrial myocytes; Ϸ70%; PϽ0.005), or by pretreatment with apocynin (Ϸ80%; PϽ0.005), a specific inhibitor of NAD(P)H oxidases ( Figure 1A) . A small reduction (10% to 20%) in basal superoxide production was observed in response to inhibition of cyclooxygenase (indomethacin; Pϭ0.047) in isolated myocytes and of mitochondrial complex I (rotenone; Pϭ0.02) in RAA homogenates. In contrast, inhibition of NO 
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synthase (NOS) with N-nitro-L-arginine methyl ester (L-NAME) tended to increase basal superoxide production (by Ϸ25% in RAA homogenates; Pϭ0. 35) . Xanthine oxidase inhibition with oxypurinol had no effect on basal superoxide production in both preparations. NADPH-stimulated superoxide release was markedly inhibited by apocynin and DPI in both preparations, whereas oxypurinol, indomethacin, and L-NAME caused very little change (Ϸ5% to 10% reduction; Figure 1B) . Rotenone resulted in a small reduction in NADPH-stimulated superoxide release in both preparations (10% to 20%; PϽ0.005).
As observed previously in vascular tissue, 23 NADPH chemiluminescence was significantly greater (Ϸ2-fold) than the NADH-evoked signal in RAA homogenates and in atrial myocytes. Further experiments showed that NADPH and NADH were the only substrates that elicited a significant increase in superoxide production in both preparations (Figure 2A ).
To further characterize myocardial NAD(P)H oxidase activity, we evaluated NADPH-dependent superoxide production in subcellular fractions of RAA and atrial myocyte homogenates ( Figure 2B ). Subcellular fractionation by ultracentrifugation into soluble (cytosolic) and particulate (membrane) fractions revealed that Ͼ95% of the NADPHstimulated oxidase activity originated from the particulate fraction in both preparations (PϽ0.005 versus cytosolic).
Oxidative fluorescent microtopography using the fluorescent probe DHE showed in situ superoxide production in cryosections of RAAs ( Figure 3A) , which was significantly attenuated after incubation with PEG-SOD (1000 U/mL).
Together, these data indicate that a membrane-associated NAD(P)H oxidase is the main source of superoxide production in RAA homogenates and right atrial myocytes isolated from patients in SR. 
Expression of NAD(P)H Oxidase Subunits in Human RAA Homogenates and Isolated Myocytes
To determine whether NAD(P)H oxidase subunits were expressed in the human atrial myocardium, we used a combined approach using antibodies directed against the p22 phox , p47 phox , and p67 phox subunits of the NAD(P)H oxidase in RAA homogenates and isolated atrial myocytes and conventional RT-PCR to detect p22 phox and gp91 phox mRNA in isolated atrial myocytes. Figure 3B shows that the p22 phox , p47 phox , and p67 phox subunits are detected in RAA homogenate and atrial myocytes. p22 phox , p47 phox , and p67 phox appeared as single bands, which were aligned to their respective positive control bands (ϩ human neutrophils). Conventional RT-PCR confirmed the presence of p22 phox and gp91 phox mRNA in purified human atrial myocytes but did not detect other gp91 phox homologues such as nox1 or nox4 ( Figure 3C) . p47 phox or p67 phox immunolocalization in isolated human atrial myocytes showed a diffuse pattern consistent with cytosolic and membrane-bound localization of these NAD(P)H oxidase subunits ( Figure 3D) . Omission of the primary antibody (negative control) resulted in no staining in 17 of 17 cells from 3 patients. Corresponding phase contrast images of the same cells are shown in the bottom panel of Figure 3D .
Atrial NAD(P)H Oxidase Activity Is Increased in Patients With AF
NADPH-stimulated superoxide production was significantly higher in RAA homogenates derived from AF patients compared with patients in SR ( Figure 4A ; Pϭ0.02), who were matched for age, LVEF (46Ϯ12% in SR and 50Ϯ13% in AF; Pϭ0.40), treatment, and known risk factors (Table 1) . Basal superoxide production also tended to be higher in the AF group, but this difference did not reach statistical significance (Pϭ0.15; Figure 4A) . LVEF was not different between AF and SR patients ( Table 1) . As expected, atrial size was significantly larger in the AF group (4.05Ϯ0.16 cm in SR patients; nϭ10 versus 5.01Ϯ0.17 cm in AF patients; nϭ14; Pϭ0.0006); however, there were no differences in LVEF (Pϭ0.97), atrial size (Pϭ0.38), or superoxide production (Pϭ0.32) between patients with permanent or paroxysmal AF. Similarly, we did not find a significant correlation between atrial size (range 3.3 to 6 cm) and basal or NADPHstimulated superoxide production (r 2 ϭ0.03 for both), suggesting that the latter is unlikely to be a consequence of atrial hypertrophy and remodeling in AF.
As observed in patients in SR, basal superoxide production in RAA homogenates from AF patients was inhibited by apocynin (Ϸ81%; Pϭ0.005) and rotenone (Ϸ40%; Pϭ0.02; Figure 4B ; Pϭ0.55 and 0.33, respectively, for comparison with the apocynin-and rotenone-induced inhibition in SR patients). Interestingly, in fibrillating RAA, pretreatment with L-NAME (but not with D-NAME; 1 mmol/L; nϭ3; data not shown) significantly reduced basal superoxide production by Ϸ40% (Pϭ0.01 versus control and Pϭ0.002 versus SR), indicating that dysfunctional NOS may become a significant source of basal superoxide production in fibrillating atria. Similar results were obtained by using N G -monomethyl-Larginine (L-NMMA; 1 mmol/L; nϭ3; data not shown).
Pretreatment with apocynin significantly decreased NADPH-stimulated superoxide release (Ϸ90%; Pϭ0.005), and an Ϸ20% reduction in NADPH-stimulated superoxide release was also observed in response to L-NAME (Pϭ0.008 versus control and Pϭ0.07 versus SR; Figure 4B ). Rotenone, oxypurinol, and antimycin-A (10 mol/L) had no significant effect.
Quantification of p22 phox and gp91 phox mRNA in RAA from patients with AF and matched controls in SR using real-time RT-PCR showed no difference in the expression of these subunits between groups (nϭ15 patients per group, arbitrary copy numbers; p22 phox 328.5Ϯ71.4 in AF versus 280.1Ϯ37.5 in SR; gp91 phox 139.9Ϯ51 in AF versus 138.6Ϯ27.1 in SR; PϭNS; Figure 5 ).
Discussion
The main findings of this study are as follows: (1) a membrane-bound gp91 phox /nox2 containing NAD(P)H oxidase is the main source of superoxide production in human atrial myocytes; (2) NAD(P)H-dependent superoxide production from RAA homogenates is increased in patients with a history of AF in the absence of changes in the mRNA expression of the p22 phox and gp91 phox /nox2 subunits; and (3) in atrial tissue from patients with AF, NOS inhibition resulted in a significant reduction in lucigenin-enhanced chemiluminescence, suggesting that NOS may be "uncoupled" and contribute to superoxide production in fibrillating atria.
These findings suggest that a myocardial NAD(P)H oxidase and, to a lesser extent, NOS and mitochondrial oxidases may play an important role in the atrial oxidative injury and electrophysiological remodeling observed in patients with AF.
Characterization of the Human Atrial NAD(P)H Oxidase
Our findings indicate that a membrane-bound gp91 phox NAD(P)H oxidase is present in human right atrial myocytes, where it constitutes the main source of superoxide production. This is evidenced by the observation that RAA superoxide production is significantly increased by the addition of NADPH or NADH but not by application of substrates of other oxidase systems. Similarly, basal and NADPHstimulated superoxide production (the latter resulting almost exclusively from the particulate fraction) were nearly abolished by apocynin and DPI but not by inhibitors of other oxidases. Pretreatment of RAA homogenates with rotenone and antimycin-A revealed a trend toward a reduction in basal superoxide production, suggesting that the contribution of mitochondrial oxidases to basal superoxide production in the human atrial myocardium is small. We also provide evidence of atrial myocyte-specific expression of the NAD(P)H oxidase subunits p22 phox , p47 phox , and p67 phox at the protein level and of p22 phox and gp91 phox /nox2 (but not nox1 or nox4) at the messenger level.
Together, our findings indicate that human atrial myocytes have the capability of producing superoxide through a membrane-bound gp91 phox /nox2 containing NAD(P)H oxidase.
Myocardial Superoxide Production, Oxidative Stress, and AF
Increased atrial superoxide production may have important implications in the ionic remodeling process, which promotes AF maintenance. Enhanced myocardial superoxide production can decrease NO bioavailability by scavenging NO (to form the potent oxidant peroxynitrite) and by "uncoupling" NOS activity, 25, 26 which in turn may lead to an increase in myocardial oxygen consumption, 27 ␤-adrenergic responsiveness, 28, 29 and thrombogenic risk. 30 Carnes et al 3 reported an increase in atrial 3-nitrotyrosine content (a marker of peroxynitrite formation in vivo) in a canine model of rapid atrial pacing that was associated with an abbreviation of the atrial ERP. Interestingly, administration of the antioxidant ascorbate attenuated atrial peroxynitrite formation and electrophysiological remodeling in these animals. Similarly, statins have been shown recently to reduce angiotensin II-stimulated (but not basal) NAD(P)H oxidase activity in human RAA 31 and to attenuate ERP reduction and AF inducibility in dogs exposed to rapid atrial pacing. 4 Together, these findings suggest the presence of a causal relationship between pro-oxidative cellular redox state, atrial ionic remodeling, and AF.
Our findings clearly show that NAD(P)H oxidase is the main source of atrial superoxide production in AF and in SR; however, they also indicate that the contribution of NOS to myocardial superoxide production is significantly increased in the fibrillating atrial myocardium. This is evidenced by a reduction in basal-and NADPH-stimulated superoxide production after pretreatment with L-NAME or L-NMMA in RAA homogenates from AF patients. These data differ significantly from those obtained in patients in SR, in whom L-NMMA tended to increase lucigenin chemiluminescence.
It is now well established that NOSs can release superoxide when deprived of their critical cofactor tetrahydropbiopterin (BH 4 ) or of their substrate L-arginine. 32 Under these conditions (referred to as "NOS uncoupling"), electron flow results in a reduction of molecular oxygen at the prosthetic heme site of the enzyme rather than in NO synthesis. In the presence of increased oxidative stress, oxidation of BH 4 can uncouple NOS to generate reactive oxygen species. 26, 33 The notion that this may occur in the fibrillating atrial myocardium is supported by the recent findings of Cai et al, 30 who showed that eNOS expression in the left atrial appendage in a porcine model of rapid pacing-induced AF did not differ from control animals despite a documented reduction in NO formation at this site.
We observed that the capacity of NAD(P)H oxidase to generate superoxide was significantly higher in patients with AF compared with matched patients in SR. Enhanced NAD(P)H oxidase activity can either be attributable to increased expression or post-translational modifications of the oxidase subunits. Real-time quantitative RT-PCR revealed no difference in p22 phox or gp91 phox mRNA between AF and SR groups, suggesting that the increase in NAD(P)H oxidase activity observed in AF may be attributable to the latter mechanism. Indeed, a key feature of cardiovascular NAD(P)H oxidase is its responsiveness to hormones, hemodynamic forces, and local metabolic changes. 5 In particular, vascular NAD(P)H oxidase activity is known to be greatly increased by angiotensin II via phosphorylation of p47 phox . 34 In agreement with these findings, we found that angiotensin II potently stimulates atrial NAD(P)H oxidase activity (Kim et al, unpublished observations, 2004) which, like its vascular counterpart, is markedly inhibited by chelerythrine, indicating that these effects are at least in part protein kinase C dependent. Together, these findings suggest that the activation of the renin-angiotensin system may be an important underlying mechanism for the increased NAD(P)H oxidase activity and ensuing atrial oxidative stress observed in human AF.
Limitations
The findings of our study should be interpreted in the context of their limitations. Because regional differences in endocardial NO production have been reported in a porcine model of AF induced by rapid right atrial pacing, 30 caution should be exerted in extrapolating our findings to the whole atrial myocardium. However, in humans, AF has been shown to cause similar changes in size, function, 35 and ion channel protein expression 14 in both atria, suggesting that remodeling may be a diffuse phenomenon.
To our knowledge, our study provides the first evidence of NOS uncoupling in the human myocardium; however, detailed investigation of the mechanisms responsible for this phenomenon was hampered by limited tissue availability because the incidence of AF in patients undergoing first-time elective coronary revascularization was Ͻ10%. Because all our SR controls patients underwent coronary artery bypass surgery, we elected to recruit AF patients from a similar cohort to match the two groups for risk factors (eg, age, atherosclerosis, and diabetes mellitus) and treatment agents (eg, statins, angiotensin-converting enzyme inhibitors, or angiotensin II receptor blockers) that are known to affect myocardial/endothelial superoxide production. 9, 31 
Conclusions
Increasing evidence indicates that NAD(P)H oxidase may play an important role in the myocardial response to stress or injury. Our findings indicate that the primary source of superoxide production in the human atrial myocardium is an NAD(P)H oxidase in patients in SR and in those with AF. However, in the fibrillating myocardium, NOS contributes significantly to basal-and NADPH-stimulated superoxide release, suggesting that increased oxidative stress in this condition may lead to NOS uncoupling with potentially important implications on myocardial function and thrombogenesis.
